COPENHAGEN, Denmark, Sept. 29, 2026 -- Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, today announced the successful close of...
Dynogen's GI, GU Products To Benefit From $50M Round (BioWorld Today)
News | 04. 20. 2004
Dynogen Pharmaceuticals
In its largest financing to date, Dynogen Pharmaceuticals Inc. secured $50 million in a Series B round, enabling it to build its pipeline and advance its two clinical com- pounds.
